<DOC>
	<DOCNO>NCT03002428</DOCNO>
	<brief_summary>The purpose study compare effect two teriparatide product , PF708 Forteo , patient osteoporosis .</brief_summary>
	<brief_title>A Comparison PF708 Forteo Osteoporosis Patients</brief_title>
	<detailed_description>This randomize , multi-center study conduct United States . Men woman osteoporosis enrol parallel-group , open-label study design compare effect PF708 Forteo 24 week treatment . Half subject randomize receive PF708 , half randomize receive Forteo .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>If female , â‰¥5 year postmenopausal time screening , DXAderived BMD value least 1 standard deviation ( SD ) average young , healthy woman If male , DXAderived BMD value least 2 SD average young , healthy men Able use pen injection device correctly Able understand sign write Informed Consent Form ( ICF ) Treatment oral bisphosphonates ( daily weekly ) within 6 month screen Any current prior human PTHderived product ( e.g. , Forteo , Teribone , Natpara ) , include investigational purpose Immobility due severe chronically disable condition ( e.g. , stroke , Parkinson 's disease , multiple sclerosis ) History metabolic bone diseases osteoporosis History malignant disease , include solid tumor hematologic malignancy ( except basal cell squamous cell carcinoma skin completely excise consider cure ) History Paget 's disease bone History prior external beam implant radiation therapy involve skeleton Active urolithiasis primary hyperparathyroidism</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>